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Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) the causative agent
of Johne’s disease, is one of the most serious infectious diseases in dairy cattle
worldwide. Due to the chronic nature of this disease and no feasible control strategy,
it is essential to have an efficient animal model which is representative of the natural
route of infection as well as a viable treatment option. In this report, we evaluated
the effect of different doses of M. paratuberculosis in their ability to colonize murine
tissues following oral delivery and the ability of Lactobacillus casei ATCC 334, a
nascent probiotic, to combat paratuberculosis. Oral inoculation of mice was able to
establish paratuberculosis in a dose-dependent manner. Two consecutive doses of
approximately 109 CFU per mouse resulted in a disseminated infection, whereas lower
doses were not efficient to establish infection. All inoculated mice were colonized with
M. paratuberculosis, maintained infection for up to 24 weeks post infection and generated
immune responses that reflect M. paratuberculosis infection in cattle. Notably, oral
administration of L. casei ATCC 334 did not reduce the level of M. paratuberculosis
colonization in treated animals. Interestingly, cytokine responses and histology indicated a
trend for the immunomodulation and reduction of pathology in animals receiving L. casei
ATCC 334 treatment. Overall, a reproducible oral model of paratuberculosis in mice was
established that could be used for future vaccine experiments. Although the L. casei
ATCC 334 was not a promising candidate for controlling paratuberculosis, we established
a protocol to screen other probiotic candidates.
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INTRODUCTION
Mycobacterium avium subspecies paratuberculosis (M. paratuber-
culosis) is the causative agent of Johne’s disease characterized by
chronic granulomatous enteritis in ruminants (Collins, 2011).
Dairy cattle are the primary species affected by this disease with a
herd-level prevalence of 91% in the USA (Lombard et al., 2013).
Because of the chronic nature of Johne’s disease and difficulty
to detect M. paratuberculosis, available control measures are lim-
ited. The currently available vaccines are only able to reduce fecal
shedding of the bacterium, but do not prevent the development
of infection (Kalis et al., 2001; Sweeney et al., 2009). Because
M. paratuberculosis is a worldwide problem in cattle and a sus-
pected agent for human Crohn’s disease (Hermon-Taylor and
Bull, 2002; Divangahi et al., 2008), alternative treatment options
are needed to control Johne’s disease in dairy herds. Recently,
various strains of lactic acid bacteria (LAB), have been shown
to inhibit the growth of M. paratuberculosis in fermented food
(Van Brandt et al., 2011), providing the potential for its use to
control infection in a suitable host. Current animal models for
Johne’s disease pathogenesis and vaccine studies are either inef-
ficient (e.g., the intraperitoneal infection of mice) or expensive
(e.g., the cow or goat models) (Hines et al., 2007). Developing
a reproducible, inexpensive animal model that mimics the nat-
ural route of infection and employing such model to identify a
potential control strategy is the main objective of this report.
Many strains of LAB have been shown to have probiotic prop-
erties (Hart et al., 2003; Ghadimi et al., 2010). The World Health
organization defines probiotics as “live microorganisms which
when administered in adequate amounts confer a health bene-
fit to the host” (FAO/WHO report, 2002). Generally, probiotics
are regarded as generally recognized as safe (GRAS) organisms
(Van Brandt et al., 2011) which would facilitate their use to
control Johne’s disease in farm animals. Earlier studies on LAB
suggested their ability to exclude pathogens (Neu, 2007), mod-
ulate the systemic and mucosal immunity (Matsuzaki and Chin,
2000; Ghadimi et al., 2010), improve the epithelial barrier func-
tion (Corr et al., 2009), reduce inflammatory responses (Yan et al.,
2011), and finally, act an antimicrobial agent (Dobson et al.,
2011). In most of these studies, mice were used to evaluate the
performance of LAB. For Johne’s disease, several animal models
have been employed, but the most extensively studied model has
been the murine model. Although this model has its limitations
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of lacking clinical signs of Johne’s disease, such as severe intestinal
lesions and diarrhea (Hines et al., 2007), we were able to pro-
duce histological and immunological patterns similar to those
displayed in ruminants (Shin et al., 2006). Comparing different
routs of murine infection with M. paratuberculosis, the intraperi-
toneal (IP) injection was able to induce reproducible infection
in all inoculated animals. Alternatively, when the oral route was
used, mouse infection was only established in approximately 58%
of animals (Mutwiri et al., 1992; Veazey et al., 1995). Because
the oral route is the natural route of infection in the target host
(cattle) (Chacon et al., 2004), we decided to optimize the murine
oral model and examine the potential of use of LAB to control
paratuberculosis.
To evaluate the efficacy of LAB ATCC 334 against M. paratu-
berculosis infection, we first established a reproducible murine
model that closely mimics the natural pathogenesis of M. paratu-
berculosis following oral inoculation (109 CFU/animal).
Infections were detected in at least one organ of all inoculated
mice in addition to the development of M. paratuberculosis-
specific cell-mediated immunity. Interestingly, LAB ATCC 334
treatments were able to modulate host immunity and reduce the
pathology of murine paratuberculosis. Whether such findings
could be reproduced in a ruminant model (e.g., goats) of Johne’s
disease remains to be examined and could provide a novel
approach to control this disease in dairy herds.
MATERIALS AND METHODS
BACTERIAL STRAINS AND CULTURING CONDITIONS
M. paratuberculosis strain K10, first passaged through a BALB/c
mouse and isolated from the mesenteric lymph node was grown
at 37◦C in Middlebrook 7H9 broth (Difco, Sparks, MD) sup-
plemented with 10% ADC (2% glucose, 5% BSA fraction V,
and 0.85% NaCl, 0.5% glycerol, 0.05% Tween 80, and 2μg/ml
mycobactin J (Allied Monitor, Fayette, MO) (Hsu et al., 2011).
For animal inoculations, bacterial cultures were harvested at an
optical density at 600 nm of 1.0, washed in phosphate-buffered
saline (PBS), and resuspended in 1/10 volume of PBS. To enu-
merate bacteria, serial dilutions of M. paratuberculosis cultures
were plated on supplemented Middlebrook 7H10 agar (Difco,
Sparks, MD). Agar plates for enumerating colonization in ani-
mal tissues were also supplemented with 5mg/ml vancomycin,
30mg/ml amphotericin B, and 10mg/ml nalidixic acid to reduce
bacterial and fungal contamination (Wu et al., 2007).
The LAB ATCC 334 was fed daily to mice undergoing ther-
apeutic treatment. Cultures were grown in 5ml MRS broth
(Difco, Sparks, MD) for 24 h at 37◦C in stagnant conditions
after which 1/100 of the culture was then transferred into fresh
media and grown for 18 h (Jim Steele-personal communication).
Cultures were then pelleted through centrifugation, washed 1×
with PBS and resuspended in 1/10 volume in skim milk for
storage at −20◦C until use. The strain used for this study was
transformed with plasmid pTRKH2 (Stephenson et al., 2011),
which encodes an erythromycin resistance marker that could be
used to quantify LAB ATCC 334 doses on MRS agar (Difco,
Sparks, MD) (2.5μg/ml erythromycin). For feeding trials, the
strain survival at room temperature was evaluated by suspending
a culture in water and incubation at room temperature for 1 week,
during which time daily serial dilutions were taken to evaluate its
viability.
ANIMAL INFECTIONS WITHM. paratuberculosis
Female BALB/c mice were purchased from Harlan Laboratories
(Indianapolis, IN) at 3 weeks of age, housed in filtered screened
shoe box plastic cages (cleaned every other day) in a pathogen-
free environment, and provided with food and water ad libitum
according to the protocol approved by the Institutional Animal
Care and Use Committee, University of Wisconsin-Madison. In
the first trial, mice (n = 10) were inoculated with a low infection
dose of M. paratuberculosis via oral gavage on two consecutive
days. Bacterial inocula were given to one group at 104 CFU/mouse
and the second group at 105 CFU/mouse per dose each day.
Mice were sacrificed at 6 weeks post infection. At time of sac-
rifice, samples from the liver, spleen, mesenteric lymph node
and intestines were collected for bacterial, histopathological, and
immunological examination (Shin et al., 2006). Since samples
were divided to test the aforementioned parameters, the possi-
bility of heterogeneous distribution of M. paratuberculosis needs
to be taken into account during interpretation of results. In the
second trial, groups of mice (n = 20) were inoculated with a
high infection dose (109 CFU/mouse/day) of M. paratuberculo-
sis via oral gavage on two consecutive days (Veazey et al., 1995).
Mouse groups (n = 3–5) were sacrificed at 1 day, 3, 6, 12, and
24 weeks post infection. At time of sacrifice, samples from the
liver, spleen, mesenteric lymph node and intestines were collected
for bacterial, histopathological, and immunological examination.
Fecal samples were also collected throughout the duration of the
study to monitor bacterial shedding. Fecal samples were decon-
taminated by resuspension in 0.75% Hexadecylcetylpyridinium
chloride (HPC) (Sigma-Aldrich), at a 1:10 ratio and standing for
24 h at room temperature (Stabel, 1997). Supernatant was then
removed and centrifuged (3000 × g) for 10min. Pellets were
washed with PBS and resuspended in fresh PBS to be used for
quantification by serial dilution plating on 7H10 agar. Samples
were conducted in duplicate from a pooled sample of feces.
Tissue sections collected for histopathology were preserved in
10% neutral buffered formalin before being embedded in paraf-
fin, cut into 4- to 5-μm sections, and stained with hematoxylin
and eosin or the Ziehl-Neelsen method for acid-fast staining.
Tissue sections were scored by a trained pathologist blindly, based
on severity and extent of inflammatory lesions (normal, lym-
phocytic inflammation, granulomatous inflammation, or granu-
loma) (Hsu et al., 2009).
FEEDING TRIALS OF L. casei ATCC 334
The L. casei ATCC 334 feeding trials included a preventative
trial, in which ATCC 334 was fed before M. paratuberculosis
challenge, a therapeutic trial, in which ATCC 334 was fed after
M. paratuberculosis challenge, and a continuous trial, in which
ATCC 334 was fed before and after M. paratuberculosis chal-
lenge. In the therapeutic treatment trial, groups of mice (n =
10) were orally inoculated with 109 CFU/mouse of M. paratu-
berculosis on two consecutive days. At 6 weeks post infection
mice began to receive daily doses of ATCC 334 resuspended in
water given ad libitum. Water intake was monitored daily for
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2014 | Volume 4 | Article 11 | 2
Cooney et al. Treating paratuberculosis with probiotics
each group of mice to ensure LAB inoculums of approximately
109 CFU/mouse. Mice (n = 3–6) were sacrificed at 12 and 24
weeks post infection and the liver, spleen, mesenteric lymph node,
and intestines were collected for bacterial, histopathological, and
immunological examinations.
For the preventative and continuous treatment trials, groups
of mice (n = 10) were fed daily doses of 109 CFU of ATCC
334 resuspended in their water bottle for 1 month prior to oral
infection with 109 CFU/mouse M. paratuberculosis on two con-
secutive days. After M. paratuberculosis infection, half of the mice
received water with no ATCC 334 (preventative treatment), while
the other half continued receiving ATCC 334 resuspended in
their water bottle for the reminder of the experiment (continu-
ous treatment). All mice were sacrificed at 12 weeks post infection
and tissues were collected for bacterial, histopathological, and
immunological examinations.
CYTOKINE ANALYSIS
At time of sacrifice, one third of the spleen was kept on ice
before harvesting splenocytes for cytokine analysis (Wu et al.,
2007). Briefly, spleens were sectioned andmashed through amesh
screen using the rubber plug of a syringe in a 60mm Petri dish
(CORNING, Corning, NY) in RPMI (Sigma-Aldrich, St. Louis,
MO) supplemented with 1% fetal bovine serum (FBS) (Sigma-
Aldrich), 1% L-glutamine (Gibco, Life Technologies), and 1%
penicillin/streptomycin (Cellgro, Manassas, VA). Single cell sus-
pensions were collected and pelleted by centrifugation followed
by red blood cells lysis with 0.83% NH4Cl. Debris was allowed
to settle before decanting mixture to a new tube. Cells were pel-
leted and resuspended in RPMI supplemented with 10% FBS, 1%
L-glutamine, 1% pen/strep, and 1% non-essential amino acids
(Gibco, Life Technologies) before seeding into 96 well flat bottom
plates (Falcon, Franklin Lakes, NJ) at a density of 106 cells/well.
Splenocytes were supplemented with 100U/ml of interlukin-2
(BD Pharmingen) and stimulated with either 10μg/ml of Johnin
purified protein derivative (PPD) (Animal and Plant Health
Inspection Services, NVSL, Ames, IA), or 10μg/ml of a posi-
tive control, Concanavalin A (Sigma-Aldrich). Stimulation doses
used in this study were based on results from preliminary stud-
ies to optimize cytokine responses (data not shown). There were
also non-stimulated, naive controls. All samples were cultured
in duplicate for 48 h in a water-jacketed incubator (Thermo
Scientific, Waltham, MA) at 37◦C with 5% C02. After 48 h, cell
cultures were transferred to 96 well round bottom plates (Nunc,
Roskilde, Denmark) and pelleted. Supernatants were collected at
stored at −20◦C until cytokine analysis.
Cytokine levels were measured using the Luminex TH1/TH2
Mouse 6-Plex Panel bead array kit as per the manufacturer
instructions (Invitrogen, Frederick, MD). This kit quantified lev-
els of interferon gamma (IFNγ), interlukin-2 (IL-2), interlukin-4
(IL-4), interlukin-5 (IL-5), interlukin-10 (IL-10), and interlukin-
12 (IL-12) from splenocyte cell culture supernatants. Cytokine
levels were determined by subtracting the background levels from
each sample and averaged among the group (Suresh et al., 2005).
DNA EXTRACTION AND PCR
At time of sacrifice, tissue samples from the liver, spleen,
mesenteric lymph node and intestines were collected and
homogenized in PBS. Briefly, mycobacterial DNA was extracted
from tissue samples through incubation with 5mg/ml of
lysozyme for 2 h at 37◦C followed by an overnight incuba-
tion with 10% SDS and 2mg/ml or proteinase-K at 56◦C.
The samples were then mixed with 0.4 volumes of 5M potas-
sium acetate, centrifuged, and supernatant was collected. DNA
was precipitated using tris-saturated phenol:chloroform:isoamyl
alcohol (25:24:1), followed by phenol removel with chloro-
form/isoamyl alcohol (24:1) and precipitation with3M sodium
acetate and 2.5 volumes of 100% ethanol. DNA was resuspended
in ddH20. Polymerase chain reaction (PCR) was performed using
the mycobacterial species-specific primers for the IS900 inser-
tion sequences. Forward primer: TACCTTTCTTGAAGGGTG
TTCGGGG, Reverse primer: TTGTGCCACAACCACCTCCG.
PCR conditions: 94◦C, 5min, 30 × (94◦C, 15 s, 60◦C, 20 s, 72◦C,
20 s) 72◦C, 10min, 4◦C hold.
STATISTICAL ANALYSIS
One-Way ANOVA analysis was performed to evaluate differences
in bacterial colonization in tissue samples and Luminex cytokine
levels during the course of the study.
P-values of<0.05 were considered to be significant (SigmaPlot
11.0 software).
RESULTS
M. paratuberculosis INFECTION FOLLOWING ORAL DELIVERY
In the first attempt to establish the oral model of murine infec-
tion, groups of mice were inoculated via oral gavage with 104
CFU/animal or 105 CFU/animal of M. paratuberculosis on two
consecutive days. Clinically, all animals’ survived oral infection
and daily observations of infected animals showed no signs of ill-
ness throughout the duration of the study. All mice were sacrificed
at 6 weeks post infection to quantify colonization levels in organs
known to harbor M. paratuberculosis (liver, spleen, intestines and
mesenteric lymph nodes). The 6 week time point was chosen
based on clear colonization in the intraperitoneal model at this
point in earlier studies (Shin et al., 2006; Scandurra et al., 2010).
However, culturing of these organs showed no detectable levels of
M. paratuberculosis (detection limit, 10 CFU/g) and all tissue PCR
analyses were negative (data not shown).
In the second attempt, a higher dose, 109 CFU/animal of
M. paratuberculosis was used via oral gavage on two consecutive
days. Challenged animals harbored detectable levels of bacteria
as early as 1 day post infection from at least one organ per ani-
mal in each group; with themesenteric lymph node and intestines
showing colonization in all animals (Figure 1). After 3 weeks post
infection, there was an overall decrease in colonization in cultured
organs compared to day 1. Importantly, M. paratuberculosis was
detected in the mesenteric lymph node of all animals by 3 weeks
post infection. In addition, M. paratuberculosis was detected in
the liver and spleen, suggesting that the bacteria had disseminated
to several body organs following oral inoculation. By 6 weeks
post infection, M. paratuberculosis showed an increase in bacte-
rial load in the mesenteric lymph node as well as in the liver and
intestines. Interestingly, none of the animals at this time point
had detectable levels of infection in the spleen (Figure 1D). At 12
weeks post infection, M. paratuberculosis colonization remained
at levels similar to earlier time point (6 weeks post infection) for
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FIGURE 1 | Organ colonization from high dose orally infected mice.
Graphs (A–D) (A, Intestine; B, Mesenteric lymph node; C, Liver; D, Spleen)
depict CFU/g obtained from plating serial dilutions of homogenized organs
(intestines, mesenteric lymph node, liver and spleen) from mice orally
infected with two consecutive doses of 109 CFU of M. avium subsp.
paratuberculosis K10 over a 24 week period. Each dot represents one
mouse, the hash mark denotes the mean, and the dotted line represents
the minimum detection limit. (∗p < 0.05).
the intestines and the liver, whereas the mesenteric lymph node
had increased levels of colonization. The spleens at 12 weeks post
infection showed detectable levels of M. paratuberculosis for two
of the five animals observed. By the final time point of 24 weeks
post infection, the liver and spleen showed an overall further
decline in colonization, possibly due to the start of bacterial clear-
ance, whereas the intestinal colonization remained steady and
the mesenteric lymph node increased significantly (p < 0.05),
reflecting its importance in establishing persistent infection. Fecal
shedding of M. paratuberculosis was also monitored over the
duration of the study. Results showed that within 24 h after receiv-
ing their first dose, mice were shedding approximately 104 CFU
per gram of feces (Figure 2). By 48 h, the mice received their sec-
ond oral dose of M. paratuberculosis which further increased the
bacterial load in the feces. However, the bacterial content greatly
decreased by 1 weeks post infection, and was not detectable at any
other point for the remainder of the study by culture or PCR (data
not shown).
IMMUNE RESPONSES TOM. paratuberculosis ORAL INFECTION
To determine the host response to M. paratuberculosis infection,
a representative group of TH1 (IFN-γ, IL-2, IL-12) and TH2
(IL-4, IL-5, IL-10) cytokines were analyzed from splenocytes col-
lected from each animal at time of sacrifice and incubated in
media supplemented with Johnin PPD for 48 h. ELISA-based
FIGURE 2 |M. avium subsp. paratuberculosis shedding in mouse fecal
samples. Pooled fecal samples were collected from mice orally infected
with two consecutive doses of 109 CFU of M. avium subsp.
paratuberculosis K10 Samples were decontaminated by HPC treatment and
serial dilution plating on 7H10 agar was performed for quantification. All
samples were run in duplicate.
cytokine profiling revealed that animals challenged with low
dose (104 CFU/animal, and 105 CFU/animal) concentrations of
M. paratuberculosis had no antigen-directed cytokine responses
(data not shown). On the other hand, the high dose group (109
CFU/mouse), showed significant release of IFN-γ (p = 0.03),
IL-2 (p = 0.02), and IL-10 (p = 0.01) in harvested spleenocytes
stimulated with Johnin compared to media only controls by
12 weeks post infection. By 24 weeks post infection, the TH1
cytokines, IFN-γ and IL-2, showed a decrease in overall lev-
els compared with 12 weeks post infection, but they were still
significantly upregulated from controls (p = 0.002, p = 0.0004).
Unfortunately, release of IL-4, IL-5, and IL-12 cytokines in
response to PPD was too low to be quantified at all time points.
Interestingly, IL-10 (representative of TH2cytokines) remained
relatively constant and still significantly up regulated from the
control (p < 0.01) at both 12 and 24 weeks post infection.
Finally, we attempted to examine the shift from TH1 to TH2
type of cytokines by estimating IFN-γ/ IL-10 ratios. Interestingly,
the TH1 responses were dominant throughout the examined
points despite the TH1 response declined by 24 weeks post infec-
tion compared to earlier time point at 12 weeks post infection
(Figure 3). Thus, oral infection induced antigen-specific immune
responses, inducing both TH1 and TH2 M. paratuberculosis spe-
cific cytokines.
PATHOLOGY OFM. paratuberculosis FOLLOWING ORAL
INFECTION
Histological evaluation of the liver, spleen, and intestines from
the low dose infection group at 6 weeks post infection revealed
normal pathology and no acid-fast bacterium detected in any
of the organs. The high dose M. avium subsp. paratuberculo-
sis oral inoculation model, like other mouse models, showed
histological lesions mostly affecting the liver, similar to those
observed following intraperitoneal inoculation (Shin et al., 2006).
Examining liver sections at 6 weeks post infection revealed nor-
mal histology in two of the four animals, while the remaining two
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FIGURE 3 | Cytokine profiles of high doseM. avium subsp.
paratuberculosis orally infected mice over 24 weeks post infection.
Graphs (A–C) depict cytokine levels of mice orally infected with two
consecutive doses of 109 CFU of M. avium subsp. paratuberculosis K10
over a 24 week period. At time of sacrifice, mouse spleens were collected
and splenocytes were isolated and stimulated with Johnin Purified Protein
Derivative (PPD) or media only for 48 h. Supernatant was collected and
used for cytokine quantification by luminex bead array. Black bars represent
the mean levels of media only background levels with their standard
deviation and gray bars represent the mean levels from stimulation with
PPD with their standard deviation. Significant increases in PPD stimulated
splenocytes were determined by comparison to media only levels.
(∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). To determine shifts in immune
response from 12 to 24 weeks, levels of IFNγ were divided by IL-10 from
individual mice (D). The mean ratio and standard deviation for each time
point is shown.
showed early stages of lymphocyte inflammation (Figure 4). At
12 weeks post infection, liver sections revealed only one animal
with undetectable lesions; while the remaining animals showed
lesions ranged from early stages of lymphocyte aggregation to
early stages of granuloma formation. By 24 weeks post infec-
tion, the granuloma formation in the liver sections was more
prominent (Figure 4). Overall, the percentage of animals show-
ing granulomatous inflammation went from 20% at 12 weeks
post infection to 66% at 24 weeks post infection. All animals
had normal pathology in the intestines and spleens at all time
points. No acid fast bacteria were detected in any of the organs
by Ziehl-Neelsen staining.
THE EFFECT OF LAB ATCC 334 ONM. paratuberculosis COLONIZATION
Because of our interest (and others) in developing an effective
control strategy against Johne’s disease, we evaluated the efficacy
of the LAB strain, ATCC 334 as a tool to controlM. paratuberculo-
sis infection. We conducted a series of trials in order to determine
the optimum feeding protocol to reduce colonization levels of
FIGURE 4 | Liver pathology from high dose oralM. avium subsp.
paratuberculosis K10 challenge at various time points. Images (A–D)
reveal liver pathology from mice orally infected with two consecutive doses
of 109 CFU of M. avium subsp. paratuberculosis K10 over a 24 week period.
H&E stained sections with 40× magnification (scale bar = 100μm) are
shown. Images of 6 and 12 weeks post infection show lymphocyte
inflammation and the image at 24 weeks post infection shows
granulomatous inflammation. (A) Non-infected (B) 6 weeks (C) 12 weeks
(D) 24 weeks.
M. paratuberculosis in mice organs. Our trials included preven-
tative (feeding LAB before challenge with M. paratuberculosis),
therapeutic (feeding LAB after challenge), and continuous (feed-
ing LAB before and after challenge) groups, in comparison to a
control group of mice challenged with M. paratuberculosis that
did not receive any LAB ATCC 334 (Figure 5). Only the high dose
(109 CFU/mouse) of oral delivery was used in these trials. In addi-
tion, we tested the survival of LAB ATCC 334 at room tempera-
ture water before starting the feeding trials to ensure LAB viability
during the feeding trials. As expected, the LAB ATCC 334 num-
bers remained constant for 2 days before dropping two logs on day
3 (data not shown). Accordingly, we replenished the culture resus-
pended in water every 2 days throughout the course of the study.
An important readout of the oral model of paratuberculo-
sis is the colonization level of M. paratuberculosis in mouse
parenchymatous organs following different treatments with LAB.
At 12 weeks post challenge (WPC), the mesenteric lymph node
had increased M. paratuberculosis colonization levels in all LAB
treatment groups compared to the control, however only the
continuous treatment showed a statistically significant increase
(Figure 6A). Interestingly, the liver of animals fed ATCC 334
prior to M. paratuberculosis challenge had no detectable lev-
els of M. paratuberculosis (PCR analysis was negative, data not
shown), unlike the control animals (Figure 6B). In addition,
the M. paratuberculosis colonization levels were similar in the
spleen of all treatment groups including the control (Figure 6C).
Intestinal colonization at this time point was unable to be
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FIGURE 5 | Experimental design of Lactobacillus casei ATCC 334
feedings. Three Lactobacillus casei ATCC 334 trials were conducted
(preventative, therapeutic and continuous) along with a control. All mice
were inoculated with two doses of 109 CFU of M. avium subsp.
paratuberculosis K10 on two consecutive days. The blue arrows represent
the period of ATCC 334 feeding, where mice received daily doses
of ∼109 CFU of ATCC 334. The black lines denote the parts of the trial
period where no ATCC 334 was given. Mice were sacrificed and
samples for colonization, histopathology and immunology were collected
at 12 and/or 24 weeks post infection.
quantified due to overgrowth of LAB in all cultured plates. By 24
WPC, the therapeutic treatment group showed similarM. paratu-
berculosis colonization in all examined organs (Figure S1).
ATCC 334 IMMUNOMODULATION DURINGM. paratuberculosis
INFECTION
In addition to colonization data, we also evaluated the cytokine
profiles for each of the different treatment groups in response
to a mixture of M. paratuberculosis specific antigens (Johnin
PPD). At 12 WPC, the inflammatory TH1 responses of IFN-
γ were similar among all treatment groups, however only IL-2
levels were significantly reduced (Figure 7). Interestingly, the
anti-inflammatory TH2 responses of IL-10 were reduced in the
preventative treatment group but not to the statistical level. By
24 WPC, no differences in cytokine responses were detected
between any of the treatment groups and the control (data not
shown).
Finally, we utilized cytokine profiles to estimate TH1/TH2
ratios in order to determine if the LAB treatments had any
effects on skewing the immune response toward cellular or
humoral responses, respectively. At 12 WPC, the preventative
ATCC 334 treatment skews the immune response more toward
an inflammatory, TH1 response, while the therapeutic feeding
regimen reduces the TH1 response (Figure S3). Interestingly,
in the continuous group, the cytokine ratios fall between the
individual levels for the preventative and therapeutic groups
and were similar to the control. By 24 WPC, the TH1/TH2
ratio of the control and therapeutic groups revealed a com-
plete shift from the responses seen at 12 WPC (Figure S2). The
cytokine profile of the control group went from being skewed
from a TH1 to a TH2 and the therapeutic group shifted from
a predominant TH2 toward TH1, suggesting natural progres-
sion of paratuberculosis infection in the control group and
immunomodulation favoring a protecting TH1 response from
ATCC 334.
THE EFFECTS OF LAB TREATMENTS ON THE DEVELOPMENT OF
paratuberculosis LESIONS
To complete the evaluation of LAB treatments in the murine
model of paratuberculosis, we evaluated the histology of tissues
across the different treatment groups. By 12WPCwithM. paratu-
berculosis, the continuous group had the highest percentage
(80%) of animals with normal pathology in the liver, followed
by the preventative treatment group (60%) which also showed no
granulomatous formation (Table 1). Interestingly, the therapeutic
treatment group had liver pathology scores similar, or worse than
that of the control group; 50% of the animals showed granuloma
formation. By 24 weeks post challenge, the therapeutic group
performed better than the control group, showing more animals
with normal pathology and less with granulomatous inflamma-
tion, revealing a possible delayed protective response. Histology
of the intestines and spleens from 12 and 24 weeks revealed nor-
mal pathology from all animals in the study. Taken together, these
data suggests the importance of administering ATCC 334 prior to
M. paratuberculosis infection.
DISCUSSION
Paratuberculosis is a chronic infectious disease that challenges the
dairy industry and has no effective control strategy. Infection of
dairy producing animals and the contamination of dairy products
with M. paratuberculosis could increase the potential exposure of
humans to M. paratuberculosis and the development of Crohn’s
disease (Chamberlin et al., 2001). Therefore, it is critical to
develop a cost effective animal model that mimics the natural
infection route and to investigate alternative treatment options. In
this study, we optimized the oral model of murine infection with
M. paratuberculosis to develop a better model for paratuberculo-
sis.We also employed thismodel to evaluate immune-modulation
of host responses using LAB ATCC 334, in reducing the impact
of M. paratuberculosis infection using an assortment of feeding
trials. Earlier reports indicated that low infectivity rates are the
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FIGURE 6 |M. avium subsp. paratuberculosis organ colonization from
different Lactobacillus casei ATCC 334 treatments at 12 weeks post
oralM. avium subsp. paratuberculosis K10 infection. Graphs (A–C)
(A-Mesenteric lymph node, B-Liver, C-Spleen) depict the CFU/g of M.
avium subsp. paratuberculosis obtained from the homogenized organs
(mesenteric lymph node, liver and spleen) of mice treated with different
ATCC 334 treatments and orally challenged with two doses of 109 CFU M.
avium subsp. paratuberculosis K10. Each dot represents one mouse, the
hash mark denotes the mean, and the dotted line represents the minimum
detection limit. (∗p < 0.05).
main drawback for the oral mouse model (Mutwiri et al., 1992;
Veazey et al., 1995). As suggested before (Harris and Lammerding,
2001) in other oral challenge models for mice, higher doses of at
least 108 CFU/animal of M. paratuberculosis are needed to estab-
lish reproducible infection. In our hands, mice infected with low
doses of 104 CFU/animal and 105 CFU/animal did not show any
detectable levels of M. paratuberculosis by culture or PCR, and
showed no antigen specific immune responses or pathological
lesions. On the other hand, the challenge with high doses (109
CFU/animal) yielded persistent infection, as indicated by cul-
ture, in at least one organ of all infected animals. By dosing
FIGURE 7 | Cytokine profiles of different Lactobacillus casei ATCC 334
treatments at 12 weeks post oral M. avium subsp. paratuberculosis
K10 infection. Graphs A–C (A. INFγ, B. IL-10, C. IL-12) depict cytokine levels
of mice orally infected with two consecutive doses of 109 CFU of M. avium
subsp. paratuberculosis K10 and treated with different ATCC 334
treatments. At 12 weeks post infection, mouse spleens were collected and
splenocytes were isolated and stimulated with Johnin Purified Protein
Derivative (PPD) or media only for 48 h. Supernatant was collected and
used for cytokine quantification by luminex bead array. Graph bars reflect
the mean of each treatment group and their standard deviation. Levels
were calculated by subtracting individual PPD stimulated levels from their
background levels. Significant differences among groups are reflected by
∗p < 0.05.
orally, we were able to isolate M. paratuberculosis from fecal sam-
ples during the first few days post infection, most likely because
of the direct passage through the GI tract. It is noteworthy to
mention here that the observed persistence and replication of
M. paratuberculosis in the mesenteric lymph node strongly sug-
gest the importance of the lymph nodes in establishing chronic
infection and represents a good target to track progression of
paratuberculosis in the murine model. Interestingly, compared
to other models of murine M. paratuberculosis, the oral route is
more comparable to the natural infection, where bacterial burden
is higher in the lymph node and intestines relative to the liver and
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Table 1 | Liver pathology results from different Lactobacillus casei
ATCC 334 treatments at 12 and 24 weeks post oralM. avium subsp.
paratuberculosis K10 infection.
Treatment Normal Lymphocytic Granulomatous
12 weeks inflammation inflammation
Control 1/5 3/5 1/5
Preventative 3/5 2/5 0/5
Therapeutic 1/6 2/6 3/6
Continuous 4/5 0/5 1/5
Treatment Normal Lymphocytic Granulomatous
24 weeks inflammation inflammation
Control 1/3 0/3 2/3
Therapeutic 2/3 0/3 1/3
Mice were orally inoculated with two doses of 109 CFU of M. avium subsp.
paratuberculosis K10 on two consecutive days from different ATCC 334 treat-
ment groups (preventative, therapeutic, continuous and control). At 12 and/or 24
weeks post infection, mice were sacrificed and tissues pathology was examined.
Each column represents the number of mice in that liver pathology category
(normal, inflammation with a predominance of lymphocytes, granulomatous
inflammation) over the total number of mice in that treatment group.
spleen (Mutwiri et al., 1992; Siguroardottir et al., 2004) as shown
before in other ruminants (e.g., goats and cows) (Corpa et al.,
2000; LaMarca et al., 2004).
In addition to colonization data, we examined the host
(immune and pathological) responses to M. paratuberculosis oral
infection. Overall host responses were similar to the responses
observed during M. paratuberculosis infection in ruminants,
[increased levels of pro-inflammatory cytokines IFN-γ and IL-2
which are the essential cytokines for controlling the intracellular
M. paratuberculosis pathogen early in infection (Coussens et al.,
2004) and progression of infection toward the late subclinical
stage where the pro-inflammatory TH1 response is diminished
and an increase in anti-inflammatory IL-10 is seen (Coussens,
2001)]. This suggests that M. paratuberculosis oral infection in
mice could be highly similar the progression of Johne’s disease
in ruminants.
Due to the success of the high dose inoculum, we chose this
model to serve as the route of infection for our LAB feeding tri-
als. We expected that mice receiving LAB ATCC 334 treatment
would have reduced colonization, since previous studies have
shown that LAB inhibits growth of M. paratuberculosis (Mariam,
2009; Van Brandt et al., 2011). Interestingly, continuous feeding
of LAB ATCC 334 produced the opposite results, where the con-
trols were colonized withM. paratuberculosis at levels significantly
lower than the LAB fed groups, especially in themesenteric lymph
node. A possible hypothesis is that ATCC 334 stimulated the gut
lymphocytes, as has been observed with L. acidophilus NCFM,
thereby enhancing migration to the mesenteric lymph node, and
providing new target cells for M. paratuberculosis infection and
proliferation (personal communications, Steele).Because LAB
strains have been shown to alter cytokine profiles in the presence
of mycobacterium (Ghadimi et al., 2010), we examined the effect
of LAB ATCC 334 in the murine oral model of paratuberculosis.
Interestingly, the preventative trial TH1/TH2 ratio at 12 weeks
showed how feeding ATCC 334 before M. paratuberculosis infec-
tion skewed the immune response toward a protective TH1
response and resulted in less histopathology than the control
or therapeutic feedings. This improvement in histopathology is
most likely due to strain specific immunomodulation of anti-
inflammatory IL-10 secretion (Hall and Ratledge, 1984; Corr
et al., 2009). Lower levels of IL-10 production are correlated with
better control of M. paratuberculosis infections (Murray, 1999).
However, at 12 WPC in the therapeutic trial, the opposite trend
was observed. Conversely, by 24 WPC, a shift in the TH1/TH2
ratio toward the inflammatory response was seen in the animals
receiving therapeutic ATCC 334 compared to the control group.
This shift reflects a delayed response in the LAB-treated groups
with the potential for a long-term immunomodulatory property.
Finally, an investigation of the changes in intestinal microbiota
of LAB treated animals would increase our understanding of the
mechanism of action of the used LAB strain.
In conclusion, there are several benefits of having a well-
established animal model for M. paratuberculosis challenge and
vaccine studies. The developed oral model described in this study
indicated that two consecutive M. paratuberculosis oral gavage
dosing of greater than 109 CFU per animal resulted in a repro-
ducible model of paratuberculosis in mice with similarity to the
Johne’s disease development in ruminants. Additionally, feeding
the LAB ATCC 334 could have favorable immunomodulation
and better pathology if they administrated before infection with
M. paratuberculosis. Although differences were observed between
controls and ATCC 334 treatment groups, further studies inves-
tigating long-term immunomodulatory properties of LAB are
needed as well as screening additional LAB strains that can
positively affect colonization.
Although mice and cattle have profound differences in GI
anatomy and microbial populations, this study acts as a prelim-
inary screening measure that can be used with mice before testing
in a ruminant model, since other parameters of infection, such
as cytokine responses and colonization accurately reflect paratu-
berculosis disease progression. Overall, there is great potential for
the use of LAB as a control option against paratuberculosis; not
only as feed additives, but also as vaccine carriers (Mierau et al.,
2005). However, care must be taken for selection of the appro-
priate strain and regimen of LAB treatments in dairy operations
affected by Johne’s disease.
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Figure S1 |M. avium subsp. paratuberculosis organ colonization from
therapeutic Lactobacillus casei ATCC 334 treatments at 24 weeks post
oralM. avium subsp. paratuberculosis K10 infection.
Figure S2 | Cytokine profiles of therapeutic Lactobacillus casei ATCC 334
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paratuberculosis K10 infection.
Figure S3 | IFNγ/IL-10 ratios for different Lactobacillus casei ATCC 334
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